Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases (Q33381801)

26 July 2017

1 reference

title

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases (English)

1 reference

26 July 2017

1 reference

1 reference

Brooke E Baetz

1

1 reference

26 July 2017

Sarah A Spinler

series ordinal

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

28

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1354-1373

1 reference

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Beyond unfractionated heparin and warfarin: current and future advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Direct thrombin inhibitors for anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Secondary prophylaxis with warfarin for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Ximelagatran: an orally active direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era...

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

New oral Xa and IIa inhibitors: updates on clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Challenges of establishing new antithrombotic therapies in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Targeting thrombin – rational drug design from natural mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11.1354

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.11.1354

1 reference

26 July 2017

1 reference